775 — CK Life Sciences Intl (Holdings) Income Statement
0.000.00%
Last trade - 00:00- HK$6.92bn
- HK$13.00bn
- HK$5.41bn
Annual income statement for CK Life Sciences Intl (Holdings), fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5,402 | 5,276 | 5,323 | 5,523 | 5,410 |
| Cost of Revenue | |||||
| Gross Profit | 1,630 | 1,626 | 1,637 | 1,693 | 1,577 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5,067 | 4,908 | 4,932 | 5,277 | 5,162 |
| Operating Profit | 335 | 368 | 391 | 246 | 249 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 238 | 205 | 68.6 | -91.5 | -18 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 163 | 132 | 17.3 | -127 | -188 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 163 | 132 | 17.3 | -127 | -187 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 163 | 132 | 17.3 | -127 | -187 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.017 | 0.012 | -0.005 | -0.027 | -0.053 |
| Dividends per Share |